Stoke Therapeutics Inc (STOK) - Total Liabilities
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has total liabilities worth $48.42 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Stoke Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Stoke Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Stoke Therapeutics Inc assets under control.
Stoke Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Stoke Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Australian United Investment Company Ltd
AU:AUI
|
Australia | AU$399.22 Million |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
USA | $12.10 Million |
|
Stanmore Resources Ltd
AU:SMR
|
Australia | AU$2.06 Billion |
|
Ola Electric Mobility Ltd
NSE:OLAELEC
|
India | Rs44.37 Billion |
|
Devyani International Limited
NSE:DEVYANI
|
India | Rs42.48 Billion |
|
Rendong Holdings Co Ltd
SHE:002647
|
China | CN¥3.80 Billion |
|
City Union Bank Limited
NSE:CUB
|
India | Rs864.60 Billion |
|
Dalian Zeus Entertainment
SHE:002354
|
China | CN¥648.57 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Stoke Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Stoke Therapeutics Inc (STOK) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stoke Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Stoke Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.98 Million | +55.12% |
| 2024-12-31 | $42.53 Million | -38.16% |
| 2023-12-31 | $68.78 Million | -3.43% |
| 2022-12-31 | $71.22 Million | +237.72% |
| 2021-12-31 | $21.09 Million | +78.00% |
| 2020-12-31 | $11.85 Million | +174.11% |
| 2019-12-31 | $4.32 Million | +74.91% |
| 2018-12-31 | $2.47 Million | -33.77% |
| 2017-12-31 | $3.73 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more